Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo

Area of Science:

• Ophthalmology
• Molecular Biology
• Gene Therapy

Background:

• Corneal neovascularization (CNV) is a significant cause of vision loss.
• Current treatments for CNV, targeting vascular endothelial growth factor A (VEGF-A), have limitations and adverse effects.
• Gene editing presents a novel therapeutic avenue for CNV.

Purpose of the Study:

• To investigate the efficacy of a CRISPR/Cas9 system in suppressing VEGFA for treating CNV.
• To evaluate the potential of gene editing as a therapeutic strategy for corneal angiogenesis.

Main Methods:

• Utilized a novel CRISPR/Cas9 system to target and deplete VEGFA.
• Assessed the impact of VEGFA depletion on human umbilical vein endothelial cell (HUVEC) proliferation, migration, and tube formation in vitro.
• Administered a dual AAV-SpCas9/sgRNA-VEGFA system via subconjunctival injection in a mouse model of suture-induced CNV.

Main Results:

• VEGFA depletion using the CRISPR/Cas9 system significantly inhibited HUVEC proliferation, migration, and tube formation in vitro.
• Subconjunctival injection of the CRISPR/Cas9 system effectively blocked suture-induced expression of VEGFA, CD31, and α-smooth muscle actin in mice.
• The treatment successfully inhibited corneal neovascularization in the mouse model.

Conclusions:

• The study demonstrates the potential of CRISPR/Cas9-mediated VEGFA gene editing for treating corneal neovascularization.
• This gene editing approach offers a promising and novel therapeutic strategy for CNV with potential for reduced side effects.
• This research establishes a foundational approach for gene editing therapies in ophthalmology.